Evidence map›Paper›PMID 23113752›Full record

Trial reportThyroid : official journal of the American Thyroid Association2013

Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

Panayiotis Savvides, Govardhanan Nagaiah, Pierre Lavertu, Pingfu Fu, John J Wright, Robert Chapman, Jay Wasman, Afshin Dowlati, Scot C Remick

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Thyroid : official journal of the American Thyroid Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 8 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 8 syntheses or guidelines pooled it, 214 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2021
    Guideline
  5. Pooled it
  6. Anaplastic Thyroid Carcinoma, Version 2.2015.Journal of the National Comprehensive Cancer Network : JNCCN · 2015
    Guideline
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a Cure.Thyroid : official journal of the American Thyroid Association · 2025
    Review
  19. Review
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Panayiotis SavvidesDivision of Hematology/Oncology, Seidman Cancer Center, University Hospitals , Cleveland, OH 44106, USA.
Govardhanan Nagaiah
Pierre Lavertu
Pingfu Fu
John J Wright
Robert Chapman
Jay Wasman
Afshin Dowlati
Scot C Remick
Case Western Reserve University · USNational Cancer Institute · US

Funding

Early Clinical Trials of New Anti-Cancer Agents with Phase I EmphasisU01CA062502 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI DOWLATI, AFSHIN · 1994 to 2013
$9.3M
NCI NIH HHS U01CA62502
6 · The paper itself

Abstract

backgroundAnaplastic thyroid cancer (ATC) is a rare but highly aggressive malignancy with a median survival of 3-5 months. The BRAF oncogene is mutated to its active form in up to 24% of ATC cases. Sorafenib is a tyrosine kinase inhibitor that acts on the RAF-1 serine/threonine kinase. In preclinical mouse models, sorafenib inhibits the growth of ATC xenografts and improves survival. No study of sorafenib in ATC has been conducted. We conducted a multi-institutional phase II trial of sorafenib in patients with ATC who had failed up to two previous therapies.

methodsThe primary endpoint of the trial was the Response Evaluation Criteria In Solid Tumors (RECIST)-defined imaging response rate. Twenty patients with ATC were treated with sorafenib 400 mg twice daily.

resultsTwo of the 20 patients had a partial response (10%) and an additional 5 of 20 (25%) had stable disease. The duration of response in the two responders was 10 and 27 months, respectively. For the patients with stable disease, the median duration was 4 months (range 3-11 months). The overall median progression-free survival was 1.9 months with a median and a 1-year survival of 3.9 months and 20%, respectively. Toxicity was manageable and as previously described for sorafenib, including hypertension and skin rash.

conclusionSorafenib has activity in ATC, but at a low frequency and similar to our previous experience with fosbretabulin. One patient with a response had previously progressed on fosbretabulin. Toxicities were both predictable and manageable.

Indexed as

AdultAgedAntineoplastic AgentsCarcinomaDrug EruptionsDrug Resistance, MultipleDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansHypertensionMaleMiddle AgedNeoplasm StagingNiacinamidePhenylurea CompoundsAntineoplastic AgentsNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsProto-Oncogene Proteins c-rafSorafenib

Identifiers

PMID23113752
PMCPMC3643255
OpenAlexW2085932739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.